| Autor: |
McKenzie AL; Virta Health, San Francisco, CA 94105, USA., Athinarayanan SJ; Virta Health, San Francisco, CA 94105, USA., McCue JJ; University of Washington School of Medicine Wyoming WWAMI, Laramie, WY 82071, USA., Adams RN; Virta Health, San Francisco, CA 94105, USA., Keyes M; Department of Bariatric and Medical Weight Loss, Indiana University Health-Arnett, Lafayette, IN 47905 USA., McCarter JP; Department of Genetics, Washington University School of Medicine, St. Louis, MO 63110, USA.; Abbott Diabetes Care, Inc., Alameda, CA 94502, USA., Volek JS; Virta Health, San Francisco, CA 94105, USA.; Department of Human Sciences, The Ohio State University, Columbus, OH 43210, USA., Phinney SD; Virta Health, San Francisco, CA 94105, USA., Hallberg SJ; Virta Health, San Francisco, CA 94105, USA.; Department of Bariatric and Medical Weight Loss, Indiana University Health-Arnett, Lafayette, IN 47905 USA. |
| Abstrakt: |
The purpose of this study is to assess the effects of an alternative approach to type 2 diabetes prevention. Ninety-six patients with prediabetes (age 52 (10) years; 80% female; BMI 39.2 (7.1) kg/m 2 ) received a continuous remote care intervention focused on reducing hyperglycemia through carbohydrate restricted nutrition therapy for two years in a single arm, prospective, longitudinal pilot study. Two-year retention was 75% (72 of 96 participants). Fifty-one percent of participants (49 of 96) met carbohydrate restriction goals as assessed by blood beta-hydroxybutyrate concentrations for more than one-third of reported measurements. Estimated cumulative incidence of normoglycemia (HbA1c <5.7% without medication) and type 2 diabetes (HbA1c ≥6.5% or <6.5% with medication other than metformin) at two years were 52.3% and 3%, respectively. Prevalence of metabolic syndrome, class II or greater obesity, and suspected hepatic steatosis significantly decreased at two years. These results demonstrate the potential utility of an alternate approach to type 2 diabetes prevention, carbohydrate restricted nutrition therapy delivered through a continuous remote care model, for normalization of glycemia and improvement in related comorbidities. |
